The reasons for reduced specificity in PSMA imaging are well known and include neovascularization and PSMA overexpression in non-prostatic tissue, e.g., benign neoplasms, i.e., thyroid and parathyroid adenomas, and in non-prostatic malignancies such as breast cancer, thyroid cancer, gliomas, lung cancer, neuroendocrine tumors, lymphoma, and renal cell carcinoma. Here, FOLH1 is linked to lung cancer.